Product/Composition:- | Tetrabenazine tablets |
---|---|
Strength:- | 25 mg, 50 mg, 75 mg |
Form:- | Tablets |
Reference Brands:- | Xenazine(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor that depletes dopamine, serotonin, and norepinephrine in nerve terminals. It effectively reduces hyperkinetic movements like chorea in Huntington’s disease, supporting symptom control, improving motor function, and enhancing quality of life in movement disorder patients worldwide.
Tetrabenazine tablets, marketed as Xenazine, are approved in the US by the FDA and in the EU via EMA for treating hyperkinetic movement disorders such as Huntington’s disease chorea. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data to ensure safety and efficacy, while the EMA ensures regional compliance with safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe use, and worldwide availability, helping improve quality of life for patients with movement disorders.